Key Points
- BD EVP Michael Feld sold 76 shares at an average price of $198.13, totaling $15,057.88, under a pre-arranged Rule 10b5-1 trading plan. He continues to own 19,568 shares worth approximately $3.88 million.
- Becton, Dickinson and Company reported quarterly EPS of $3.23, exceeding estimates of $3.14, while revenue reached $4.98 billion, up 5.4% year over year. The company projects fiscal 2026 EPS of $12.62–$12.72.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $185.07; BDX recently opened at $195.10, near its 52-week high of $200.47.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 76 shares of Becton, Dickinson and Company stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $198.13, for a total value of $15,057.88. Following the sale, the executive vice president owned 19,568 shares of the company's stock, valued at approximately $3,877,007.84. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Feld also recently made the following trade(s):
- On Monday, September 28th, Michael Feld sold 76 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $183.70, for a total value of $13,961.20.
- On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85.
Becton, Dickinson and Company Stock Down 0.7%
Shares of BDX opened at $195.10 on Wednesday. The firm's 50 day moving average price is $185.89 and its 200 day moving average price is $170.36. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $200.47.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm earned $3.68 earnings per share. The business's revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
BDX has been the subject of a number of recent research reports. Jefferies Financial Group reiterated a "buy" rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. Bank of America raised their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Monday, August 31st. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Weiss Ratings upgraded Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $185.07.
Get Our Latest Stock Report on Becton, Dickinson and Company
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of BDX. Maryland Capital Advisors Inc. boosted its position in shares of Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 139 shares during the period. Trifecta Capital Advisors LLC increased its position in shares of Becton, Dickinson and Company by 59.0% during the third quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 62 shares during the period. Meeder Asset Management Inc. increased its position in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD bought a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of Becton, Dickinson and Company in the second quarter valued at $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.
BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
